

## PRIOR AUTHORIZATION CRITERIA

**BRAND NAME**  
(generic)

**CIALIS 2.5 mg, 5 mg**  
(tadalafil)

**Status: CVS Caremark Criteria**

**Type: Initial Prior Authorization with Quantity Limit**

### POLICY

#### FDA-APPROVED INDICATIONS

##### **Erectile Dysfunction**

Cialis is indicated for the treatment of erectile dysfunction (ED).

##### **Benign Prostatic Hyperplasia**

Cialis is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

##### **Erectile Dysfunction and Benign Prostatic Hyperplasia**

Cialis is indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH).

#### Limitation of Use

If Cialis is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of Cialis decreases from 4 weeks until 26 weeks, and the incremental benefit of Cialis beyond 26 weeks is unknown.

#### COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- Cialis (tadalafil) 2.5 mg or 5 mg is being prescribed for daily use for symptomatic benign prostatic hyperplasia (BPH)  
[Note: Examples of signs and symptoms are incomplete emptying, weak stream, straining, urinary frequency, intermittency, urgency, or acute urinary retention.]

Quantity Limits apply.

30 tablets per 25 days

90 tablets per 75 days

#### REFERENCES

1. Cialis [package insert]. Indianapolis, IN: Eli Lilly and Company; April 2016.
2. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; [http://online.lexi.com/lco/action/index/dataset/complete\\_ashp](http://online.lexi.com/lco/action/index/dataset/complete_ashp) [available with subscription]. Accessed April 2017.
3. Micromedex Healthcare Series [database online]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically. <http://www.thomsonhc.com> [available with subscription]. Accessed April 2017.

4. American Urological Association Guideline Management of Benign Prostatic Hyperplasia (BPH). 2010. <https://www.auanet.org/Documents/education/clinical-guidance/Benign-Prostatic-Hyperplasia.pdf>. Accessed April 2017.